Navigation Links
BioLife Solutions Announces $2.2 million Total Revenue for the Third Quarter of 2013
Date:11/14/2013

BOTHELL, Wash., Nov. 14, 2013 /PRNewswire/ -- BioLife Solutions, Inc. (OTCQB: BLFS), a leading developer, manufacturer and marketer of proprietary clinical grade hypothermic storage and cryopreservation freeze media for cells and tissues, and contract aseptic media manufacturer, today announced revenue for the third quarter of 2013 of $2.2 million, including core HypoThermosol® and CryoStor® product revenue of $1.0 million. This marked the first quarter that core revenue has exceeded $1.0 million. Total revenue was up 29% compared to the third quarter of 2012, and down 7% from the second quarter of 2013.

(Logo: http://photos.prnewswire.com/prnh/20090814/BIOLIFELOGO)

Summary of Achievements for the Third Quarter of 2013

  • Core product revenue was $1.0 million, setting a new record for the Company, driven by demand from the regenerative medicine market segment.
  • Execution of a strategic partnership agreement with SAVSU Technologies, Inc., wherein BioLife will exclusively market and distribute SAVSU's proprietary precision thermal packaging products to the stem cells and regenerative medicine markets.
  • Expansion of the Company's relationship with STEMCELL Technologies, who recently selected BioLife's CryoStor cGMP freeze media for use in the launch of over 50 new primary cell products (isolated from bone marrow, peripheral blood, umbilical cord blood, and umbilical cord tissue), to be marketed to the research community.
  • Addition of Robert Preti, Ph.D., President and Chief Scientific Officer of Progenitor Cell Therapy, a wholly owned subsidiary of NeoStem, Inc., to our Scientific Advisory Board.
  • Mike Rice, BioLife Solutions President and CEO, remarked on the Company's third quarter revenue by stating, "We are pleased to see our core product revenue to hit the milestone of $1.0 million this quarter. We see continued adoption of our proprietary HypoThermosol and CryoStor biopreservation media products in the regenerative medicine segment, with our products now incorporated in nearly 100 hospital-approved and clinical trial stage products and therapies.  Revenue from this market segment is difficult to forecast, based on the pace of customer clinical trials, but it's clear that our products are emerging as new standards for clinical grade biopreservation media in regenerative medicine applications.  We also see a significant opportunity to raise the bar in the shipment of precious biologic payloads via the distribution of reusable, super-insulating containers from SAVSU Technologies.  We estimate this opportunity represents a new potential addressable market of $50 million to $100 million."

    Third Quarter 2013 and Year to Date Financial ResultsTotal revenue for the third quarter and first nine months of 2013 was $2.2 million and $6.7 million, respectively, compared to $1.7 million and $3.6 million in the same periods of 2012. The increase was due primarily to increased contract manufacturing revenue and higher direct product sales to the regenerative medicine and biobanking markets. In addition, the increase in the total revenue for the nine months of 2013 included license revenue of $0.6 million.

    Gross margin as a percentage of revenue increased in the third quarter of 2013 to 41.0% compared with 35.4% during the third quarter of 2012. This increase was due primarily to a change in the mix of revenue in 2013, including a significant increase in core product sales, which has a higher gross margin compared to contract manufacturing services. Gross margin as a percentage of revenue increased slightly during the nine months ended September 30, 2013 to 42.7% compared to 42.6% during the same period in 2012. Gross margin in the nine months ended September 30, 2013 includes the positive impact of recognition of significant license revenue during the nine months with no associated costs. In addition, gross margin increased during the nine months ended September 30, 2013 due to the increase in core product sales, offset by increased contract manufacturing services, which has a higher cost of sales, compared to core product sales.

    Operating expenses in the quarter ended September 30, 2013 and the first nine months of 2013 were $1.0 million and $2.8 million, respectively, compared with $0.7 million and $2.2 million for the same periods of 2012. This increase was primarily attributable to higher corporate costs, higher depreciation and rent costs related to the new facility, and higher office-related expenses.

    During the third quarter of 2013 and the first nine months of 2013, the Company reported an operating loss of $0.1 million and $606, respectively, compared to operating losses of $0.1 million and $0.6 million in the third quarter and first nine months of 2012. Net loss was $0.3 million, or $0.00 per share, for the third quarter of 2013 and $0.6 million, or $0.01 per share in the first nine months of 2013, compared to a net loss of $0.4 million, or $0.01 per share, for the third quarter of 2012 and $1.1 million, or $0.02 per share, in the first nine months of 2012, respectively.

    About BioLife SolutionsBioLife Solutions develops, manufactures and markets biopreservation media and high performance thermal packaging products for cells, tissues, and organs. The Company's proprietary HypoThermosol® and CryoStor® platform of solutions are highly valued in the biobanking, drug discovery, and regenerative medicine markets. BioLife's products are serum-free and protein-free, fully defined, and are formulated to reduce preservation-induced cell damage and death.  BioLife's enabling technology provides academic and clinical researchers significant improvement in shelf life and post-preservation viability and function of cells, tissues, and organs.  For more information please visit www.biolifesolutions.com, and follow BioLife on Twitter.

    This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning our financial and business outlook for 2013, and other anticipated developments related to us, our business or customers. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These statements are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including the factors described in our risk factors set forth in our filings with the Securities and Exchange Commission from time to time, including our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. We undertake no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof, other than as may be required by applicable law.

     Media & Investor RelationsDaphne TaylorSenior Vice President, Chief Financial Officer(425) 402-1400 dtaylor@biolifesolutions.com  BioLife Solutions, Inc.Statement of OperationsThree MonthsEnded September 30,Nine MonthsEnded September 30,201320122013

    2012

    RevenueProduct sales

    $

    2,170,491$

    1,676,480$

    6,051,354$

    3,599,770Licensing revenue––5,000609,16715,000Total revenue2,170,4911,681,4806,660,5213,614,770Cost of product sales1,281,6341,086,0313,817,7372,073,909Gross profit888,857595,4492,842,7841,540,861Operating expensesResearch and development160,528110,689361,404353,837Sales and marketing208,080145,735625,600379,774General and administrative630,342487,7331,856,3861,441,852Total operating expenses998,950744,1572,843,3902,175,463Operating loss(110,093)(148,708)(606)(634,602)Other income (expenses)Other income ––––––94,253Interest expense(185,554)(185,554)(556,664)(547,875)Gain on disposal of property and equipment––431––368Amortization of deferred financing costs(14,263)(18,397)(42,322)(60,142)Total other income (expenses)(199,817)(203,520)(598,986)(513,396)Net Loss

    $

    (309,910)$

    (352,228)$

    (599,592)$

     

    (1,147,998)Basic and diluted net loss per common share

    $

    (0.00)$

    (0.01)$

    (0.01)$

     

    (0.02)Basic and diluted weighted average common shares used to calculate net loss per common share70,106,31269,679,85470,005,20769,679,854 

     

      Selected Balance Sheet DataSeptember 30,December 31,20132012Cash and cash equivalents$

    79,287$

    196,478Accounts receivable1,026,858600,153Inventories409,195656,397Total current assets1,655,4171,627,759Total current liabilities1,228,9051,365,338Promissory notes payable, related parties10,603,12710,603,127Accrued interest, related parties3,316,0552,759,391Total liabilities16,066,39415,655,852Total shareholders' equity (deficiency)(12,859,370)(12,486,023)  Selected Cash Flow DataNine Months Ended September 30, 20132012Cash provided by operating activities$

    67,460$

    686,128Cash used in investing activities(235,109)(1,170,463)Cash provided by financing activities50,458475,000Net decrease in cash and equivalents(117,191)(9,335)
    '/>"/>

    SOURCE BioLife Solutions, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. BioLife Solutions and SAVSU Technologies Announce Exclusive Distribution Agreement
    2. BioLife Solutions Announces the Addition of Robert Preti, Ph.D. to its Scientific Advisory Board
    3. BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress
    4. BioLife Solutions Announces 2012 Full Year Results; 10th Consecutive Quarter of Record Revenue
    5. BioLife Solutions Appoints Rick Stewart To Board of Directors
    6. BioLife Solutions Completes First $1 Million Revenue Quarter
    7. Endo Health Solutions to Present at the 2013 Credit Suisse Healthcare Conference
    8. Pi2 Solutions Presents on Pharmacovigilance Literature Screening at Major European Risk Management Meeting
    9. HighPoint Solutions et InnoPeritus sassocient pour fournir des services consultatifs inédits sur le marché européen des sciences du vivant
    10. HighPoint Solutions and InnoPeritus Partner to Provide Unprecedented Consultative Services in the European Life Sciences Market
    11. Predilytics Launches Two Healthcare Analytics Solutions
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/24/2016)... , June 24, 2016 Dehaier Medical ... the "Company"), which develops, markets and sells medical devices ... , signed a strategic cooperation agreement with Hongyuan ... "Hongyuan Supply Chain") on June 20, 2016, to develop ... the strategic cooperation agreement, Dehaier will leverage Hongyuan Supply ...
    (Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
    (Date:6/24/2016)... --  Pulmatrix, Inc ., (NASDAQ: PULM ), ... today that it was added to the Russell Microcap ... set of U.S. and global equity indexes on June ... for Pulmatrix," said Chief Executive Officer Robert Clarke ... in developing drugs for crucial unmet medical needs, and ...
    Breaking Medicine Technology:
    (Date:6/25/2016)... ... ... Bruton Memorial Library on June 21 due to a possible lice infestation, as reported by ... lice: the parasite’s ability to live away from a human host, and to infest common ... the event that lice have simply gotten out of control. , As lice are a ...
    (Date:6/25/2016)... , ... June 25, 2016 , ... As a lifelong ... Cum Laude and his M.D from the David Geffen School of Medicine at UCLA. ... to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai ...
    (Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... Conventional wisdom ... of success. In terms of the latter, setting the bar too high can result ... more than just slow progress toward their goal. , Research from PsychTests.com ...
    (Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
    (Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
    Breaking Medicine News(10 mins):